Skip to main content

Bronchospasmolytika und Antiasthmatika

  • Chapter
  • 96 Accesses

Zusammenfassung

Bronchospasmolytika werden zur Behandlung des Asthma bronchiale und der chronisch-obstruktiven Atemwegskrankheit (COPD) eingesetzt. Bei beiden Erkrankungen ist es das Ziel, die Bronchialobstruktion, die beim Asthma wesentlich reversibler ist als bei der COPD, zu beseitigen und das typische Spätstadium der COPD mit Ateminsuffizienz und Cor pulmonale so weit wie möglich zu bessern.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Agertoft L., Pedersen S. (2000): Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N. Engl. J. Med. 343: 1064–1069.

    Article  PubMed  CAS  Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2003): Arzneiverordnungen. 20. Aufl., Deutscher Ärzte-Verlag, Köln, S. 610.

    Google Scholar 

  • Arzneiverordnung in der Praxis (AVP) (2001): Asthma bronchiale, Sonderheft 1. Auflage, September 2001.

    Google Scholar 

  • Barnes PJ. (1995): Beta-adrenergic receptors and their regulation. Am. J. Respir. Crit. Care Med. 152: 838–860.

    PubMed  CAS  Google Scholar 

  • Barnes P.J., Pauwels R.A. (1994): Theophylline in the management of asthma: time for reappraisal? Eur. Respir. J. 7: 579–591.

    Article  CAS  Google Scholar 

  • Bundesamt für Arzneimittel und Medizinprodukte (BfArM) (1998): Arzneimittel mit problematischer Bioverfügbarkeit. 9. Bekanntmachnung gemäß § 26, Abs. 3 AMG vom 19.1.1998.

    Google Scholar 

  • Brocklebank D., Wright J., Cates Ch. (2001): Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. Brit. Med. J. 323: 1–7.

    Article  Google Scholar 

  • Buhl R., Kardos P., Magnussen H., Matthys H., Sauer R., Schauer P. et al. (1999): Feste Kombination inhalierbarer Kortikoide und langwirkender ß2-Sympathomimetika zur Langzeittherapie des Asthma bronchiale. Pneumologie 53: 210–212.

    PubMed  CAS  Google Scholar 

  • Busse W.W., Brazinsky S., Jacobson K., Stricker W., Schmitt K., Vanden Bürgt J. et al. (1999): Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new prolellant. J. Allergy Clin. Immunol. 104: 1215–1222.

    Article  PubMed  CAS  Google Scholar 

  • Clarke P.S., Ratowsky D.A. (1990): Effect of fenoterol hydrobromide and sodium cromoglycate individually and in combination on postexercise asthma. Ann. Allergy 64(2 Pt. 2): 187–190.

    PubMed  CAS  Google Scholar 

  • Crout J.R. (1974): Fixed combination prescription drugs: FDA policy. J. Clin. Pharmacol. 14: 249–254.

    PubMed  CAS  Google Scholar 

  • Debelic M., Hertel G., König J. (1988): Double-blind crossover study comparing sodium cromoglycate, reproterol, reproterol plus sodium cromoglycate, and placebo in exercise-induced asthma. Ann. Allergy 61: 25–29.

    PubMed  CAS  Google Scholar 

  • Drazen J.M., Israel E., O’Byrne P.M. (1999): Treatment of asthma with drugs modifying the leukotrien pathway. N. Engl. J. Med. 340: 197–206.

    Article  PubMed  CAS  Google Scholar 

  • Ducharme F.M., Hicks G.C. (2001): Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma. The Cochrane Library, Issue 2. Oxford: Update Software.

    Google Scholar 

  • Gehrke I., Böhm E., Sybrecht G.W. (1986): Stress-induced asthma — placebo-controlled double-blind comparison of prevention using fenoterol, disodium cromoglycate and a combination of the two. Prax. Klin. Pneumol. 40: 129–134.

    PubMed  CAS  Google Scholar 

  • Global Initiative for Chronic Obstructive Lung Disease (GOLD 2001) (2001): http://www.goldcopd.com/workshop/html.

  • Grahnén A., Eckernas S.A., Brundin R.M., Ling-Andersson A. (1994): An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br. J. Clin. Pharmacol. 38: 521–525.

    Article  PubMed  Google Scholar 

  • Hanania N.A., Chapman K.R., Sturtridge W.C. et al. (1995): Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J. Allergy Clin. Immunol. 96: 571–579.

    Article  PubMed  CAS  Google Scholar 

  • Jarvis B., Markham A. (2000): Montelukast — a review of its therapeutic potential in persistent asthma. Drugs 59: 891–928.

    Article  PubMed  CAS  Google Scholar 

  • Leitlinien COPD (2002): http://www.leitlinien.de/themen/infocopd.htm.

  • Leach C, Davidson P.J., Boudreau RJ. (1998): Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFCbeclomethasone. Eur. Respir. J. 12: 1346–1353.

    Article  CAS  Google Scholar 

  • Lemmer B. (1990): Chronopharmakologische Aspekte der Theophyllintherapie. In: Blume H. (Hrsg.): Bioäquivalenz retardierter Theophyllin-Fertigarzneimittel. Govi, Frankfurt, S. 75–82.

    Google Scholar 

  • Lemmer B., Wettengel R. (2001): Erkrankungen der Atemwege. In: Lemmer B., Brune K. (Hrsg.): Pharmakotherapie — Klinische Pharmakologie. 11. Aufl., Urban & Fischer Verlag, München, S. 313–329.

    Google Scholar 

  • Lipworth B.J. (1999): Modern drug treatment of chronic asthma. Brit. Med. J. 318: 380–383.

    Article  PubMed  CAS  Google Scholar 

  • Markham A., Jarvis B. (2000): Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma. Drugs 60:1207–1233.

    Article  PubMed  CAS  Google Scholar 

  • McCowan C, Neville R.G., Thomas G.E., Crombie I.K., Clark R.A. et al. (1998): Effect of asthma and its treatment on growth: four year follow up of cohort of children from general practices in Tayside, Scotland. Brit. Med. J. 316: 668–672.

    Article  PubMed  CAS  Google Scholar 

  • National Heart, Lung, and Blood Institute (1997): Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma [EPR-2]. National Institutes of Health, pub. no. 97–4051.

    Google Scholar 

  • Parfitt K. (1999): Martindale. The complete drug reference. 32nd ed. Pharmaceutical Press, London, pp. 765–774.

    Google Scholar 

  • Robinson D.S., Campbell D., Barnes P.J. (2001): Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebocontrolled trial. Lancet 357: 2007–2011.

    Article  PubMed  CAS  Google Scholar 

  • Rodrigo G., Rodrigo C, Burschtin O. (1999): A meta-analysis of the effects of ipratropium bromide in adults with acute asthma. Am. J. Med. 107: 363–370.

    Article  PubMed  CAS  Google Scholar 

  • Schmidt H. (1994): Retardtheophyllin ist nicht gleich Retardtheophyllin. Atemwegs Lungenkr. 20: 223–231.

    Google Scholar 

  • Sears M.R., Rea H.H., Fenwick J. et al. (1987): 75 Deaths in asthmatics prescibed home nebulisers. Brit. Med. J. 294: 477–480.

    Article  CAS  Google Scholar 

  • Serafín W.E. (1996): Drugs used in the treatment of asthma. In: Hardman J.H., Limbird L.E., Molinoff P. B., Ruddon R.W., Goodman Gilman A. (eds.): Goodman & Gilman The Pharmacological Basis of Therapeutics, 9th ed. McGraw Hill, New York, pp. 659–682.

    Google Scholar 

  • Smolensky M.H., D’Alonso G.E. (1997): Progress in the chronotherapy of nocturnal asthma. In: Redfern P., Lemmer B. (eds.): Physiology and Pharmacology of Biological Rhythms. Handbook of Experimental Pharmacology, Vol. 125, Springer, Berlin, Heidelberg, New York, pp. 205–249.

    Google Scholar 

  • The Childhood Asthma Management Program Research Group (2000): Long-term effects of budesonide or nedocromil in children with asthma. N. Engl. J. Med. 343: 1054–1063.

    Article  Google Scholar 

  • Weinberger M., Hendeles L. (1996): Theophylline in asthma. N. Engl. J. Med. 334: 1380–1388.

    Article  PubMed  CAS  Google Scholar 

  • Wettengel R., Berdel D., Hofmann D., et al. (1998): Asthmatherapie bei Kindern und Erwachsenen. Empfehlungen der Deutschen Atemwegsliga in der Deutschen Gesellschaft für Pneumologie. Med. Klinik 93: 639–650.

    Article  CAS  Google Scholar 

  • Williams M.H. (1989): Increasing severity of asthma from 1960 to 1987. N. Engl. J. Med. 320:1015–1020.

    Article  PubMed  Google Scholar 

  • Wilson A.M, Lipworth B.J., (1999): 24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids. Thorax 54: 20–26.

    Article  PubMed  CAS  Google Scholar 

  • Wohl M.E. B., Majzoub J.A. (2000): Asthma, steroids, and growth. N. Engl. J. Med. 343: 1113–1114.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lemmer, B. (2004). Bronchospasmolytika und Antiasthmatika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2003. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18512-0_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18512-0_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-40188-9

  • Online ISBN: 978-3-642-18512-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics